PILOT STUDY ON BREAST CANCER, CHEMOTHERAPY, AGE AND UFOV

关于乳腺癌、化疗、年龄和 UFOV 的试点研究

• 批准号: 6683744
• 负责人: Carolyn Elizabeth Adams-Price
• 金额: $ 7.03万
• 依托单位: MISSISSIPPI STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-07-01 至 2005-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6683744
• 关键词: age difference; behavioral /social science research tag; breast neoplasms; clinical research; cognition; cognition disorders; depression; diagnosis design /evaluation; drug adverse effect; female; functional ability; human subject; human therapy evaluation; neoplasm /cancer chemotherapy; neuropsychological tests; patient oriented research; transportation /recreation safety; vehicular accident; visual perception; women's health

This RO3 application addresses the NIA (PAR-02-049) objective, "Cancer in the Elderly" (#7) and is relevant to "Basic research in Behavioral Medicine" (#8), "Cognition in Context" (#12), and "Improved Measures and Methods" (#24). The incidence of breast cancer rises dramatically for post-menopausal women and increases with age. Exposure adjusted crash risk rises with age, and scores on cognitive indicators that are highly associated with important daily activities, such as driving, also tend to decline with age. Chemotherapy is a standard treatment for breast cancer and has been associated with poorer performance on neuropsychological tests. However, effects of chemotherapy on cognitive test performance that is most closely associated with everyday functioning, such as driving, have not been examined nor have interactions between age and chemotherapy on cognitive functioning. We will conduct an innovative pilot study to explore whether chemotherapy for breast cancer is associated with impaired performance on a cognitive test that is highly related to performance of important activities, including driving. We will use as a measure the UFOV, a test of visual attention/cognitive processing speed, that correlates highly with IADLs, including driving as well as crash risk. Despite its possible relevance, the UFOV has not been used in chemotherapy studies. This study will focus on three age groups--< 50, 51-69, and 70 and above and will explore age by chemotherapy interactions. The sample will include 35-50 breast cancer survivors who have completed chemotherapy, and 35-50 age-, race-, and education-matched controls. Participants will also be tested on other cognitive tests to compare findings of this study to previous studies. Data on driving behavior, subjective neuropsychological symptoms, depression and positive protective factors will be collected to explore relationships between actual deficits, perceived deficits, protective factors, and driving behavior. Findings of chemotherapy-associated deficits may be important for the safety and independence of breast cancer survivors and may assist in designing interventions. This study will provide critical information for planning a definitive study of effects of chemotherapy and of age/chemotherapy interactions on cognitive functions.

该RO 3应用解决了NIA（PAR-02-049）目标“老年人癌症”（#7），并与“行为医学基础研究”（#8）、“情境中的认知”（#12）和“改进的措施和方法”（#24）相关。绝经后妇女的乳腺癌发病率急剧上升，并随着年龄的增长而增加。暴露调整后的撞车风险随着年龄的增长而上升，与驾驶等重要日常活动高度相关的认知指标得分也往往随着年龄的增长而下降。化疗是乳腺癌的标准治疗方法，并且与神经心理学测试的较差表现有关。然而，化疗对与日常功能（如驾驶）密切相关的认知测试表现的影响尚未得到研究，年龄和化疗对认知功能的相互作用也未得到研究。我们将进行一项创新的试点研究，以探讨乳腺癌化疗是否与认知测试中的表现受损相关，该测试与重要活动（包括驾驶）的表现高度相关。我们将使用UFOV作为衡量标准，这是一种视觉注意力/认知处理速度的测试，与IADL高度相关，包括驾驶和碰撞风险。尽管它可能相关，UFOV尚未用于化疗研究。这项研究将集中在三个年龄组-< 50岁，51-69岁，70岁及以上， 探索年龄与化疗的相互作用。样本将包括35-50名完成化疗的乳腺癌幸存者，以及35-50名年龄，种族和教育匹配的对照组。参与者还将接受其他认知测试，以将本研究的结果与以前的研究进行比较。将收集驾驶行为、主观神经心理症状、抑郁和积极保护因素的数据，以探讨实际缺陷、感知缺陷、保护因素和驾驶行为之间的关系。化疗相关缺陷的发现可能对安全性和独立性很重要 乳腺癌幸存者，并可能有助于设计干预措施。本研究将为规划化疗和年龄/化疗相互作用对认知功能影响的确定性研究提供关键信息。